RJA
VKTX icon

Raymond James & Associates’s Viking Therapeutics VKTX Stock Holding History

Raymond James & Associates’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-12,000
Closed -$9K – 3757
2019
Q3 		$9K Hold
12,000
– – ﹤0.01% 3569
2019
Q2 		$6K Buy
+12,000
New +$103K ﹤0.01% 3604

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Raymond James & Associates's VKTX Position: Q3 2024 in Review

Raymond James & Associates increased its Viking Therapeutics (VKTX) stake by 43% in Q3 2024, buying an estimated $7.81M and bringing the position to 441,590 shares worth $28M. The position accounts for 0.02% of the portfolio, ranked #654.

Raymond James & Associates first reported a position in VKTX in Q3 2018 and has held it in 25 quarters since. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Raymond James & Associates held 441,590 shares of Viking Therapeutics worth $28M as of Q3 2024.
  • Raymond James & Associates bought 133,144 Viking Therapeutics shares in Q3 2024, an estimated $7.81M.
  • Viking Therapeutics made up 0.02% of Raymond James & Associates's portfolio in Q3 2024, its #654 holding.
  • Raymond James & Associates first reported a position in Viking Therapeutics in Q3 2018 and has held it in 25 quarters since.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.